Literature DB >> 15169929

The significance of vasoactive intestinal peptide in immunomodulation.

Mario Delgado1, David Pozo, Doina Ganea.   

Abstract

First identified by Said and Mutt some 30 years ago, the vasoactive intestinal peptide (VIP) was originally isolated as a vasodilator peptide. Subsequently, its biochemistry was elucidated, and within the 1st decade, their signature features as a neuropeptide became consolidated. It did not take long for these insights to permeate the field of immunology, out of which surprising new attributes for VIP were found in the last years. VIP is rapidly transforming into something more than a mere hormone. In evolving scientifically from a hormone to a novel agent for modifying immune function and possibly a cytokine-like molecule, VIP research has engaged many physiologists, molecular biologists, biochemists, endocrinologists, and pharmacologists and it is a paradigm to explore mutual interactions between neural and neuroendocrine links in health and disease. The aim of this review is firstly to update our knowledge of the cellular and molecular events relevant to VIP function on the immune system and secondly to gather together recent data that support its role as a type 2 cytokine. Recognition of the central functions VIP plays in cellular processes is focusing our attention on this "very important peptide" as exciting new candidates for therapeutic intervention and drug development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15169929     DOI: 10.1124/pr.56.2.7

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  131 in total

1.  The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice.

Authors:  Amali E Samarasinghe; Scott A Hoselton; Jane M Schuh
Journal:  Peptides       Date:  2010-10-13       Impact factor: 3.750

Review 2.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

3.  Mechanisms of VIP-induced inhibition of the lymphatic vessel pump.

Authors:  Pierre-Yves von der Weid; Sonia Rehal; Peter Dyrda; Stewart Lee; Ryan Mathias; Mozibur Rahman; Simon Roizes; Mohammad S Imtiaz
Journal:  J Physiol       Date:  2012-03-25       Impact factor: 5.182

4.  Biological pathway-based genome-wide association analysis identified the vasoactive intestinal peptide (VIP) pathway important for obesity.

Authors:  Yong-Jun Liu; Yan-Fang Guo; Li-Shu Zhang; Yu-Fang Pei; Na Yu; Ping Yu; Christopher J Papasian; Hong-Wen Deng
Journal:  Obesity (Silver Spring)       Date:  2010-04-08       Impact factor: 5.002

5.  Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells.

Authors:  Sheri Tinnell Dorsam; Emilie Vomhof-Dekrey; Rebecca J Hermann; Jodie S Haring; Travis Van der Steen; Erich Wilkerson; Goran Boskovic; James Denvir; Yulia Dementieva; Donald Primerano; Glenn Paul Dorsam
Journal:  Mol Immunol       Date:  2010-02-01       Impact factor: 4.407

Review 6.  VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Authors:  Alain Couvineau; Marc Laburthe
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

7.  Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders.

Authors:  Alejo Chorny; Elena Gonzalez-Rey; Amelia Fernandez-Martin; David Pozo; Doina Ganea; Mario Delgado
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

8.  Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia.

Authors:  Christopher T Petersen; Jian-Ming Li; Edmund K Waller
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

9.  Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells.

Authors:  Elena Gonzalez-Rey; Alejo Chorny; Amelia Fernandez-Martin; Doina Ganea; Mario Delgado
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

10.  Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients.

Authors:  Jian-Ming Li; Mohammad S Hossain; Lauren Southerland; Edmund K Waller
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.